Amylyx Pharmaceuticals, Inc.
AMLX
Rang in aandelen
#4349
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aandeelprijs
$28.83
Marktkapitalisatie
$3.62B
Verandering (1 dag)
5.49%
Verandering (1 jaar)
87.57%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Categorie
Healthcare
P/B-ratio voor Amylyx Pharmaceuticals, Inc. (AMLX)
P/B-ratio op October 2026 TTM: 12.57
Volgens de meest recente financiële rapporten en aandelenkoers van Amylyx Pharmaceuticals, Inc. is de huidige P/B-ratio (TTM) 12.57. Eind 2023 had het bedrijf een P/B-ratio van 2.28.
P/B-ratiohistoriek voor Amylyx Pharmaceuticals, Inc. van 2019 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
